Expanded Access Program

MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...

BOSTON, Mass. — September 21, 2026 Tiziana Life Sciences announced that the last patient has completed the last visit...

Irvine, California, USA — July 27, 2026 July 27, 2026 – AnHorn Medicines has announced the successful first subject...

BOSTON – July 24, 2026 Zevra Therapeutics, Inc. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal...

CAMBRIDGE, Mass., United States – May 5, 2026 Amylyx Pharmaceuticals Inc. has announced the launch of a U.S. Expanded...

LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...

LAGUNA HILLS, Calif., March 19, 2026 Adagio Medical Holdings, Inc. announced successful outcomes from Expanded Access Program (EAP) cases...

ROSWELL, Ga., September 8, 2025 — Saol Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has...